Brookline Capital Markets Predicts NTLA Q2 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Brookline Capital Markets dropped their Q2 2026 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a note issued to investors on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($0.80) for the quarter, down from their prior forecast of ($0.75). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.17) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics’ Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($2.84) EPS, FY2027 earnings at $0.97 EPS, FY2028 earnings at $5.53 EPS, FY2029 earnings at $14.89 EPS and FY2030 earnings at $25.07 EPS.

A number of other equities analysts also recently commented on the company. Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective on the stock in a research report on Friday. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a report on Monday, June 15th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Friday, July 17th. Finally, The Goldman Sachs Group boosted their price target on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, Intellia Therapeutics currently has an average rating of “Hold” and a consensus price target of $20.85.

Intellia Therapeutics Price Performance

NTLA stock opened at $12.02 on Monday. Intellia Therapeutics has a 1 year low of $7.95 and a 1 year high of $28.25. The firm has a market capitalization of $1.68 billion, a PE ratio of -3.58 and a beta of 1.81. The business has a 50 day simple moving average of $13.59 and a 200-day simple moving average of $13.46.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.80). The business had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business’s revenue was down 46.4% on a year-over-year basis. During the same period last year, the company posted ($0.98) EPS.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares in the company, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.50% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Intellia Therapeutics during the second quarter worth about $260,721,000. ARK Investment Management LLC raised its stake in shares of Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after acquiring an additional 2,288,146 shares during the period. Vanguard Group Inc. raised its stake in shares of Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares during the period. State Street Corp lifted its holdings in shares of Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock worth $57,705,000 after acquiring an additional 1,447,967 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after acquiring an additional 107,333 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.